• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Gilead Sciences

Gilead Sciences

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. European Medicines Agency Validates Gilead ’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)

    European Medicines Agency Validates Gilead ’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)

  2. Gilead Sciences to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9

    Gilead Sciences to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9

  3. Chi-Med appoints Industry Veteran Paul Carter to Board of Directors

    Chi-Med appoints Industry Veteran Paul Carter to Board of Directors

  4. UPDATE: Drugmakers, retailers yank European stocks from 1-year high

    UPDATE: Drugmakers, retailers yank European stocks from 1-year high

  5. EUROPE MARKETS: Drugmakers, Retailers Yank European Stocks From 1-year High

    EUROPE MARKETS: Drugmakers, Retailers Yank European Stocks From 1-year High

  6. Pennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate

    Pennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate

  7. Gates Foundation to Invest Up to $140 Million in HIV-Prevention Device

    Gates Foundation to Invest Up to $140 Million in HIV-Prevention Device

  8. Extremely expensive Biogen rare disease drug could invite tweet by President-elect Trump, analyst says

    Extremely expensive Biogen rare disease drug could invite tweet by President-elect Trump, analyst says

  9. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.